New tablet study: absorption and food effects
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new form of the drug nurandociguat tablet to see how well it is absorbed compared to the old tablet, and whether food changes how it works. Healthy volunteers are needed to take the tablets and have their blood levels checked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 58 years old.
- You must be in good general health (no major medical problems).
- Your body mass index (BMI) should be between 18 and 29.9.
- You must weigh at least 132 pounds (60 kg).
- You cannot be on any regular medications or have had diarrhea or constipation in the last 2 weeks.
- You must be willing to eat the meals provided during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called EC5026 in people with and without chronic kidney disease (CKD) to see how the body handles it. It helps understand if dose adjustments are needed for people with impaired kidney function.
This study tests HRS-7535, a new oral tablet that may help protect kidneys in people with chronic kidney disease. GLP-1 medications were originally developed for diabetes but may also benefit kidney function and overall health.
This study tests whether a traditional Chinese medicine called Niaoduqing Granules can help improve kidney function in people over 60 with chronic kidney disease. It may offer a new way to manage the condition without dialysis.
This study checks if a new drug called nurandociguat is safe to take with nitroglycerin for people with stable coronary artery disease. It will help doctors understand how the combination affects the body.
This study tests how two different tablet versions of the study drug BGB-58067 enter the body and how food affects the drug. Healthy volunteers take the drug to help understand the best way to give it in future trials.
This study tests how a new experimental drug (INCB123667) works and is tolerated in adults with severe kidney problems or end-stage kidney disease. Researchers want to understand how the drug moves through the body and whether it's safe for people in your situation.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.